Alignment Healthcare, Inc. (ALHC) Stock Price & How to Invest
Last updated November 2026
Short answer
Alignment Healthcare (ALHC) is a fast-growing, technology-driven Medicare Advantage insurer that turned profitable in early 2026, then saw its stock fall about 67.5% year to date (to roughly $6.58 on November 20, 2026) after its 2027 Star Ratings collapsed and third quarter medical costs ran high. Anyone looking at it now is weighing ~37% revenue growth against a ratings setback the company says will cost more than $200 million in 2028 payments, a lawsuit it has filed to reverse it, and a lowered profit outlook.
ALHC stock price
As of 2026-11-20, Alignment Healthcare, Inc. (ALHC) last closed at $6.37, down 61.9% over the past year. Over the past 52 weeks it has traded between $6.37 and $24.56.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Alignment Healthcare, Inc.'s investor relations page. Walnut is informational, not investment advice.
ALHC key stats
At $6.37 on November 20, 2026, Alignment Healthcare, Inc. (ALHC) has a market cap of $1.3B and a P/E of 45.5 on trailing earnings (11.5 on forward earnings).
- Market cap
- $1.3B
- P/E (trailing)
- 45.5
- P/E (forward)
- 11.5
- EPS (trailing 12 months)
- $0.14
- Price to book
- 4.8
- Beta
- 1.04
Market cap, P/E and yield are measured at the $6.37 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Alignment Healthcare, Inc. (ALHC)?
The last two weeks for Alignment Healthcare, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- ALHC closed at $6.37 on November 20, 2026, down 13.5% over the past five trading days (from $7.36).
Alignment Healthcare, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Alignment Healthcare, Inc. (ALHC) do?
Alignment Healthcare operates Medicare Advantage health plans, mostly in California and a handful of other states, serving about 301,200 members as of the third quarter of 2026. Its model pairs a customized clinical care approach with a purpose-built technology platform (branded AVA) and local provider partnerships, aiming to deliver better health outcomes at lower cost than legacy insurers. High Star Ratings are central to the thesis because they drive bonus payments and help attract members, which is why the October 2026 release of 2027 ratings hit so hard: the share of Alignment's members in plans rated at least 4 stars fell from 98% in 2026 to 25% in 2027. Alignment has sued CMS in U.S. District Court for D.C., arguing the stars methodology was changed through technical notes rather than rulemaking, and its complaint says the drop will cost more than $200 million in 2028 payments.
The investment picture is one of a growth company whose earnings inflection has stalled. Revenue grew about 33% year over year in Q1 2026 to ~$1.24 billion, and the company posted its first quarterly net income (~$11 million) after years of losses. Q2 2026 extended the run: revenue of ~$1.34 billion, up about 32%, net income of ~$37 million and adjusted EPS of $0.25 against a $0.20 estimate. Q3 2026, reported October 29, kept the top line growing (revenue of ~$1.36 billion, up ~36.7% and ahead of the ~$1.31 billion estimate) but swung to a GAAP net loss of ~$8 million, with adjusted EPS of $0.05 against $0.04 expected. Management blamed higher costs mainly on claims volatility after a migration to the Facets claims platform, plus catastrophic and skilled nursing costs, and set full-year adjusted EBITDA guidance near $100 million at the midpoint, well below the ~$148 million analysts had expected. The stock is down about 67.5% year to date and about 59% over one year as of November 20, 2026. At roughly 47x trailing and 12x forward earnings and under 0.3x sales, the valuation no longer assumes flawless execution, but it now hinges on whether the ratings are restored, claims costs stabilize, and the 2028 revenue hole can be absorbed.
What's driving Alignment Healthcare, Inc. (ALHC)?
1. Membership growth engine
ALHC has compounded health plan membership at roughly 30% per year since its 2021 IPO, reaching about 301,200 members in Q3 2026, up from 294,100 in the prior quarter. Sustained enrollment gains are the primary lever behind the revenue trajectory, and analysts tracked by Yahoo Finance expect revenue of about $6.58 billion in 2027 versus roughly $5.27 billion for 2026. After the Stars setback, management said it reevaluated its 2027 bids, planning slower California growth, targeted expansion in other states (including San Antonio and four Charlotte-area counties) and a more balanced product mix, alongside a plan aimed at Asian American seniors in Los Angeles and Orange Counties.
2. Margin and profitability inflection
Adjusted EBITDA rose about 88% year over year in Q1 2026 to ~$38 million, and the company reported its first quarterly net income. Q2 2026 followed with ~$36.6 million of net income and adjusted EPS of $0.25 versus $0.20 expected. Q3 2026 broke the streak: adjusted EBITDA of ~$21.8 million (a ~1.6% margin) missed estimates, operating margin turned slightly negative, and GAAP results swung to a ~$8 million loss. The company's CFO said full-year guidance assumes the elevated claims expense of Q3 continues, and analysts expect a loss of about $0.17 per share in Q4, so the seasonal shape of medical costs now decides how durable these margins look.
3. Star Ratings: from moat to contested asset
Alignment had maintained high Star Ratings while some larger rivals slipped, and that quality edge was a core part of the thesis. The 2027 ratings released in October 2026 reversed it: members in plans rated at least 4 stars fell from 98% to 25%, and the key California HMO contract fell to 3.5 stars, which management tied mainly to triple-weighted measures such as the Health Outcomes Survey and Part D. The company is challenging the result in federal court in D.C., asking that the ratings be vacated and recalculated before the 2028 selling season, after CMS denied a request to exclude ten contested measures. A win would restore much of the bonus economics; a loss means more than $200 million of lower 2028 payments, by the company's own estimate.
4. Technology-led cost control
The AVA platform and concierge care model are designed to manage chronic conditions and lower medical spend per member. If the technology continues to bend the medical cost curve as membership scales, operating leverage could widen; this is the core assumption embedded in the valuation.
What are the risks to Alignment Healthcare, Inc. (ALHC)?
The Star Ratings collapse is now the most concrete risk: if the lawsuit fails, lower 2027 ratings cut 2028 bonus payments by more than $200 million according to the complaint, and weaker ratings can make plans less attractive during enrollment. Medical costs have already moved against the company: Q3 2026 brought a net loss on higher catastrophic and skilled nursing costs and claims volatility after a systems migration, and margins are thin (about 0.6% net over the trailing twelve months). Membership is geographically concentrated (heavy California exposure), so state-level competition or regulatory shifts carry outsized impact. CMS policy on Star Ratings, rate benchmarks, risk coding and Medicare Advantage audits directly affects revenue and bonus payments. Sentiment has reset sharply: UBS cut its target to $9 from $22 in October 2026 and then to $8 after the Q3 report, and the 52-week low of about $6.01 sits near the current price. It also competes against far larger, better-capitalized insurers that can pressure pricing and benefits.
What is the Alignment Healthcare, Inc. (ALHC) forecast?
12 analysts publish price targets on ALHC, averaging $10.79 as of November 2026, or +69.4% against the $6.37 share price on November 20, 2026. The published targets run from $8.00 to $17.00, a wide spread, and the ratings split 9 buy, 6 hold, 0 sell. Over the last six months there have been 0 raises and 11 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full ALHC forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is ALHC a buy or a sell?
We give no verdict on Alignment Healthcare, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Membership growth engine. ALHC has compounded health plan membership at roughly 30% per year since its 2021 IPO, reaching about 301,200 members in Q3 2026, up from 294,100 in the prior quarter. The most optimistic published target, $17.00, assumes this works close to its best case.
The case against. The Star Ratings collapse is now the most concrete risk: if the lawsuit fails, lower 2027 ratings cut 2028 bonus payments by more than $200 million according to the complaint, and weaker ratings can make plans less attractive during enrollment. The most pessimistic target, $8.00, is roughly what ALHC is worth if this bites instead.
Read the full bull and bear case on ALHC, including what would have to change to break either one. Walnut is not an investment adviser.
Has Alignment Healthcare, Inc. (ALHC) split its stock?
No. Alignment Healthcare, Inc. (ALHC) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is Alignment Healthcare, Inc. (ALHC) valued?
Market cap, P/E and dividend yield at today's price are in the ALHC key stats above. The business figures below come from Alignment Healthcare, Inc.'s reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$4.94B, up ~37% YoY in the latest quarter
- Q3 2026 revenue: ~$1.36B; adjusted EPS $0.05 vs $0.04 expected
- Net income (TTM): ~$29M (~0.6% net margin); Q3 net loss ~$8M
- Cash and debt: ~$743M cash, ~$331M debt
- 2026 adjusted EBITDA guidance: ~$100M at the midpoint
As of November 2026: ALHC kept growing through 2026, yet the share price fell from a 52-week high near $25 to about $6.58 by November 20, 2026 after the 2027 Star Ratings drop and a Q3 that swung to a loss. The stock trades at under 0.3 times sales and about 12 times forward earnings, and the 12 analysts tracked by Yahoo Finance had a mean target near $10.79. The pending lawsuit against CMS and the trend in claims costs are the next markers.
Who competes with Alignment Healthcare, Inc. (ALHC)?
National Medicare Advantage incumbents
UnitedHealth Group (UnitedHealthcare), Humana, CVS Health (Aetna), and Centene dominate MA with vast scale, capital, and provider networks. They can out-spend on benefits and marketing, though several have faced Star Rating and margin pressure that opened room for focused challengers.
Insurtech and value-based MA challengers
Smaller technology-forward Medicare Advantage players such as Clover Health, and historically Bright Health, pursue a similar tech-plus-value-based-care model. They compete for the same growth narrative and investor attention, with mixed records on profitability.
Regional and provider-led plans
Local and regional MA plans, provider-sponsored plans, and value-based care groups compete for members in ALHC's core markets (notably California), where enrollment is concentrated and local relationships and Star Ratings matter most.
What stocks are similar to Alignment Healthcare, Inc. (ALHC)?
Other names that sit close to ALHC: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Alignment Healthcare, Inc. (ALHC)
There are three common ways to get ALHC exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ALHC sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where ALHC fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Alignment Healthcare, Inc. (ALHC)
ALHC is a scaling Medicare Advantage operator that reached a profitability inflection in the first half of 2026, but the 2027 Star Ratings drop (members in 4-star-plus plans fell from 98% to 25%) and a third quarter net loss on elevated claims have turned it into a ~$1.4 billion company priced around 12x forward earnings, where the outcome of its CMS lawsuit and medical-cost discipline now drive the case.
More on Alignment Healthcare, Inc. (ALHC)
Whether ALHC is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ALHC a buy or a sell?, and where the stock could go from here in the ALHC stock forecast.
For income investors, whether ALHC pays a dividend and how the payout looks is covered in does ALHC pay a dividend? And to weigh ALHC against a peer, read the full side-by-side comparisons: ALHC vs UNH and ALHC vs HUM.
Wondering how ALHC fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Alignment Healthcare, Inc.
Ask Walnut's AI anything about ALHC and see how it fits what you own.
FAQ
What does Alignment Healthcare do?
+
It runs Medicare Advantage health plans for seniors, combining a clinical care model, provider partnerships, and its AVA technology platform to try to deliver better outcomes at lower cost. Its members are concentrated in California and a few other states.
Is ALHC profitable?
+
It reached a profitability inflection in 2026, reporting roughly $11 million of net income in Q1 and about $37 million in Q2 after years of losses, then a net loss of about $8 million in Q3 as medical costs rose. Trailing net income is near $29 million, analysts expect a loss in Q4, and the 2027 Star Ratings drop threatens 2028 bonus payments, so durability is still the open question.
How fast is ALHC growing?
+
Revenue grew about 33% year over year in Q1 2026, about 32% in Q2 and about 37% in Q3, reaching ~$4.94 billion over the trailing twelve months, and membership has compounded near 30% annually since its 2021 IPO, reaching about 301,200 in Q3 2026. Analysts tracked by Yahoo Finance expect about $5.27 billion of revenue for 2026 and about $6.58 billion for 2027.
Why is ALHC's P/E so high?
+
Because profits are thin and Q3 2026 was a loss, trailing earnings are small: about $0.14 per share, which put the trailing P/E near 47x at the November 20, 2026 price of $6.58. That is far lower than the 100x-plus multiple of mid-2026, because the stock fell sharply after the Star Ratings news. On forward estimates the multiple is about 12x.
What are Star Ratings and why do they matter for ALHC?
+
CMS Star Ratings measure plan quality and drive bonus payments plus member appeal during enrollment. Alignment had maintained high ratings, but in the 2027 ratings the share of its members in plans rated at least 4 stars fell from 98% to 25%. It has sued CMS to vacate the ratings, and its complaint says the drop will cost more than $200 million in 2028 payments.
Who are ALHC's main competitors?
+
Large national insurers like UnitedHealth, Humana, CVS/Aetna, and Centene, plus tech-forward MA challengers such as Clover Health and regional or provider-led plans, especially in California.
What are the biggest risks for ALHC?
+
The 2027 Star Ratings drop and the uncertain outcome of the CMS lawsuit, rising medical costs that compress thin margins, heavy geographic concentration in California, CMS policy and rate changes, and competition from far larger insurers.
How can I invest in ALHC?
+
ALHC trades on the Nasdaq and can be bought through a standard brokerage account. Walnut is not an investment adviser; this page is descriptive information to help you research the company, not a recommendation to buy or sell.
Why did ALHC stock fall in 2026?
+
The main driver was the October 2026 release of 2027 Medicare Advantage Star Ratings, which cut the share of Alignment's members in 4-star-plus plans from 98% to 25%. A Q3 net loss on elevated claims costs and a full-year adjusted EBITDA outlook near $100 million added to the decline. As of November 20, 2026, the stock was down about 67.5% year to date and 59% over one year, near $6.58, even though revenue kept growing more than 30%.
How did Alignment Healthcare do in its latest quarter?
+
In Q3 2026, reported October 29, Alignment posted revenue of about $1.36 billion, up roughly 36.7% year over year and ahead of the ~$1.31 billion estimate, with adjusted EPS of $0.05 against a $0.04 consensus. Adjusted EBITDA of ~$21.8 million missed estimates and GAAP results swung to a ~$8 million net loss, as claims volatility after a systems migration and higher catastrophic and skilled nursing costs pushed medical spending up. Membership reached about 301,200.
What did Alignment Healthcare say about 2027?
+
After the Star Ratings setback, management said it reevaluated its 2027 bids and growth strategy, with slower growth in California, targeted expansion in other states, network and product changes in certain markets, and a more balanced product mix. It expects operational investments to stabilize costs and improve Stars metrics over time, but said those benefits are not in near-term forecasts.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Alignment Healthcare, Inc.'s investor relations page or your broker before making investment decisions.